CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer

Hua Zhang; Camilla L. Christensen; Ruben Dries; Matthew G. Oser; Jiehui Deng; Brian Diskin; Fei Li; Yuanwang Pan; Xuzhu Zhang; Yandong Yin; Eleni Papadopoulos; Val Pyon; Cassandra Thakurdin; Nicholas Kwiatkowski; Kandarp Jani; Alexandra R. Rabin; Dayanne M. Castro; Ting Chen; Heather Silver; Qingyuan Huang; Mirna Bulatovic; Catríona M. Dowling; Belen Sundberg; Alan Leggett; Michela Ranieri; Han Han; Shuai Li; Annan Yang; Kristen E. Labbe; Christina Almonte; Vladislav O. Sviderskiy; Max Quinn; Jack Donaghue; Eric S. Wang; Tinghu Zhang; Zhixiang He; Vamsidhar Velcheti; Peter S. Hammerman; Gordon J. Freeman; Richard Bonneau; William G. Kaelin; Kate D. Sutherland; Ariena Kersbergen; Andrew J. Aguirre; Guo Cheng Yuan; Eli Rothenberg; George Miller; Nathanael S. Gray; Kwok Kin Wong

doi:10.1016/j.ccell.2019.11.003

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer

Hua Zhang, Camilla L. Christensen, Ruben Dries, Matthew G. Oser, Jiehui Deng, Brian Diskin, Fei Li, Yuanwang Pan, Xuzhu Zhang, Yandong Yin, Eleni Papadopoulos, Val Pyon, Cassandra Thakurdin, Nicholas Kwiatkowski, Kandarp Jani, Alexandra R. Rabin, Dayanne M. Castro, Ting Chen, Heather Silver, Qingyuan HuangMirna Bulatovic, Catríona M. Dowling, Belen Sundberg, Alan Leggett, Michela Ranieri, Han Han, Shuai Li, Annan Yang, Kristen E. Labbe, Christina Almonte, Vladislav O. Sviderskiy, Max Quinn, Jack Donaghue, Eric S. Wang, Tinghu Zhang, Zhixiang He, Vamsidhar Velcheti, Peter S. Hammerman, Gordon J. Freeman, Richard Bonneau, William G. Kaelin, Kate D. Sutherland, Ariena Kersbergen, Andrew J. Aguirre, Guo Cheng Yuan, Eli Rothenberg, George Miller, Nathanael S. Gray, Kwok Kin Wong

Research output: Contribution to journal › Article › peer-review

Abstract

Cyclin-dependent kinase 7 (CDK7) is a central regulator of the cell cycle and gene transcription. However, little is known about its impact on genomic instability and cancer immunity. Using a selective CDK7 inhibitor, YKL-5-124, we demonstrated that CDK7 inhibition predominately disrupts cell-cycle progression and induces DNA replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously triggering immune-response signaling. These tumor-intrinsic events provoke a robust immune surveillance program elicited by T cells, which is further enhanced by the addition of immune-checkpoint blockade. Combining YKL-5-124 with anti-PD-1 offers significant survival benefit in multiple highly aggressive murine models of SCLC, providing a rationale for new combination regimens consisting of CDK7 inhibitors and immunotherapies.

Original language	English (US)
Pages (from-to)	37-54.e9
Journal	Cancer Cell
Volume	37
Issue number	1
DOIs	https://doi.org/10.1016/j.ccell.2019.11.003
State	Published - Jan 13 2020

Keywords

CDK7
YKL-5-124
anti-tumor immunity
cell cycle
genome instability
immune checkpoint blockade
immunotherapy
replication stress
single-cell analysis
small cell lung cancer

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

Access to Document

10.1016/j.ccell.2019.11.003

Fingerprint Dive into the research topics of 'CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this

Zhang, H., Christensen, C. L., Dries, R., Oser, M. G., Deng, J., Diskin, B., Li, F., Pan, Y., Zhang, X., Yin, Y., Papadopoulos, E., Pyon, V., Thakurdin, C., Kwiatkowski, N., Jani, K., Rabin, A. R., Castro, D. M., Chen, T., Silver, H., ... Wong, K. K. (2020). CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell, 37(1), 37-54.e9. https://doi.org/10.1016/j.ccell.2019.11.003

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. / Zhang, Hua; Christensen, Camilla L.; Dries, Ruben; Oser, Matthew G.; Deng, Jiehui; Diskin, Brian; Li, Fei; Pan, Yuanwang; Zhang, Xuzhu; Yin, Yandong; Papadopoulos, Eleni; Pyon, Val; Thakurdin, Cassandra; Kwiatkowski, Nicholas; Jani, Kandarp; Rabin, Alexandra R.; Castro, Dayanne M.; Chen, Ting; Silver, Heather; Huang, Qingyuan; Bulatovic, Mirna; Dowling, Catríona M.; Sundberg, Belen; Leggett, Alan; Ranieri, Michela; Han, Han; Li, Shuai; Yang, Annan; Labbe, Kristen E.; Almonte, Christina; Sviderskiy, Vladislav O.; Quinn, Max; Donaghue, Jack; Wang, Eric S.; Zhang, Tinghu; He, Zhixiang; Velcheti, Vamsidhar; Hammerman, Peter S.; Freeman, Gordon J.; Bonneau, Richard; Kaelin, William G.; Sutherland, Kate D.; Kersbergen, Ariena; Aguirre, Andrew J.; Yuan, Guo Cheng; Rothenberg, Eli; Miller, George; Gray, Nathanael S.; Wong, Kwok Kin.

In: Cancer Cell, Vol. 37, No. 1, 13.01.2020, p. 37-54.e9.

Research output: Contribution to journal › Article › peer-review

Zhang, H, Christensen, CL, Dries, R, Oser, MG, Deng, J, Diskin, B, Li, F, Pan, Y, Zhang, X, Yin, Y, Papadopoulos, E, Pyon, V, Thakurdin, C, Kwiatkowski, N, Jani, K, Rabin, AR, Castro, DM, Chen, T, Silver, H, Huang, Q, Bulatovic, M, Dowling, CM, Sundberg, B, Leggett, A, Ranieri, M, Han, H, Li, S, Yang, A, Labbe, KE, Almonte, C, Sviderskiy, VO, Quinn, M, Donaghue, J, Wang, ES, Zhang, T, He, Z, Velcheti, V, Hammerman, PS, Freeman, GJ, Bonneau, R, Kaelin, WG, Sutherland, KD, Kersbergen, A, Aguirre, AJ, Yuan, GC, Rothenberg, E, Miller, G, Gray, NS & Wong, KK 2020, 'CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer', Cancer Cell, vol. 37, no. 1, pp. 37-54.e9. https://doi.org/10.1016/j.ccell.2019.11.003

Zhang, Hua ; Christensen, Camilla L. ; Dries, Ruben ; Oser, Matthew G. ; Deng, Jiehui ; Diskin, Brian ; Li, Fei ; Pan, Yuanwang ; Zhang, Xuzhu ; Yin, Yandong ; Papadopoulos, Eleni ; Pyon, Val ; Thakurdin, Cassandra ; Kwiatkowski, Nicholas ; Jani, Kandarp ; Rabin, Alexandra R. ; Castro, Dayanne M. ; Chen, Ting ; Silver, Heather ; Huang, Qingyuan ; Bulatovic, Mirna ; Dowling, Catríona M. ; Sundberg, Belen ; Leggett, Alan ; Ranieri, Michela ; Han, Han ; Li, Shuai ; Yang, Annan ; Labbe, Kristen E. ; Almonte, Christina ; Sviderskiy, Vladislav O. ; Quinn, Max ; Donaghue, Jack ; Wang, Eric S. ; Zhang, Tinghu ; He, Zhixiang ; Velcheti, Vamsidhar ; Hammerman, Peter S. ; Freeman, Gordon J. ; Bonneau, Richard ; Kaelin, William G. ; Sutherland, Kate D. ; Kersbergen, Ariena ; Aguirre, Andrew J. ; Yuan, Guo Cheng ; Rothenberg, Eli ; Miller, George ; Gray, Nathanael S. ; Wong, Kwok Kin. / CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. In: Cancer Cell. 2020 ; Vol. 37, No. 1. pp. 37-54.e9.

@article{a2e2e7d46e184958a909e3ba7589f60a,

title = "CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer",

abstract = "Cyclin-dependent kinase 7 (CDK7) is a central regulator of the cell cycle and gene transcription. However, little is known about its impact on genomic instability and cancer immunity. Using a selective CDK7 inhibitor, YKL-5-124, we demonstrated that CDK7 inhibition predominately disrupts cell-cycle progression and induces DNA replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously triggering immune-response signaling. These tumor-intrinsic events provoke a robust immune surveillance program elicited by T cells, which is further enhanced by the addition of immune-checkpoint blockade. Combining YKL-5-124 with anti-PD-1 offers significant survival benefit in multiple highly aggressive murine models of SCLC, providing a rationale for new combination regimens consisting of CDK7 inhibitors and immunotherapies.",

keywords = "CDK7, YKL-5-124, anti-tumor immunity, cell cycle, genome instability, immune checkpoint blockade, immunotherapy, replication stress, single-cell analysis, small cell lung cancer",

author = "Hua Zhang and Christensen, {Camilla L.} and Ruben Dries and Oser, {Matthew G.} and Jiehui Deng and Brian Diskin and Fei Li and Yuanwang Pan and Xuzhu Zhang and Yandong Yin and Eleni Papadopoulos and Val Pyon and Cassandra Thakurdin and Nicholas Kwiatkowski and Kandarp Jani and Rabin, {Alexandra R.} and Castro, {Dayanne M.} and Ting Chen and Heather Silver and Qingyuan Huang and Mirna Bulatovic and Dowling, {Catr{\'i}ona M.} and Belen Sundberg and Alan Leggett and Michela Ranieri and Han Han and Shuai Li and Annan Yang and Labbe, {Kristen E.} and Christina Almonte and Sviderskiy, {Vladislav O.} and Max Quinn and Jack Donaghue and Wang, {Eric S.} and Tinghu Zhang and Zhixiang He and Vamsidhar Velcheti and Hammerman, {Peter S.} and Freeman, {Gordon J.} and Richard Bonneau and Kaelin, {William G.} and Sutherland, {Kate D.} and Ariena Kersbergen and Aguirre, {Andrew J.} and Yuan, {Guo Cheng} and Eli Rothenberg and George Miller and Gray, {Nathanael S.} and Wong, {Kwok Kin}",

note = "Funding Information: We thank the NYU Langone Health Preclinical Imaging Laboratory (partially funded by National Institutes of Health (NIH)/National Cancer Institute (NCI) 5P30CA016087 and NIH P41 EB017183) and the Genome Technology Center (partially supported by P30CA016087) for library preparation and sequencing. This work is supported by a Lung Cancer Research Foundation grant (H.Z.), NCI/NIH K99CA201618 (C.L.C.), K08CA222657 (M.G.O.), U01CA213333 (K.K.W. and N.S.G.), and P01 CA154303 (K.K.W.). This work is also supported by the Bridge Project (K.K.W. and N.S.G.), a collaboration between The Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center (DF/HCC). H.Z. C.L.C. R.D. N.S.G. and K.K.W. supervised the work, designed all the experiments, and interpreted the data. H.Z. C.L.C. R.D. M.G.O. J.D. B.D. F.L. Y.P. K.J. A.R.R. T.C. M.B. and C.M.D. conducted experiments. E.P. V.P. C.T. and H.S. performed MRI. R.D. D.M.C. G.-C.Y. and R.B. performed bioinformatics analysis. N.K. T.Z. and Z.H. contributed to compound synthesis. X.Z. Y.Y. and E.R. conducted single-cell imaging. H.Z. and K.E.L. conducted MRI analysis. M.G.O. V.O.S. G.M. K.D.S. A.K. A.J.A. and W.G.K. provided critical expertise and/or reagents. All the authors contributed to manuscript preparation. H.Z. C.L.C. R.D. and K.K.W. wrote the manuscript. K.K.W. is a founder and equity holder of G1 Therapeutics and has sponsored research agreements with MedImmune, Takeda, TargImmune, Bristol-Myers Squibb (BMS), Mirati, Merus, and Alkermes, and consulting and sponsored research agreements with AstraZeneca, Janssen, Pfizer, Novartis, Merck, Ono, and Array. N.G.S. is a founder, science advisory board member and equity holder in Gatekeeper, Syros, Petra, C4, B2S, and Soltego. The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voronoi, Her2llc, Deerfield, and Sanofi. G.M. has research contract agreements with GlaxoSmithKline, Pfizer, and Puretech Health. V.V. has an advisory/consulting role at Genentech, Merck, BMS, Astrazeneca, Foundation Medicine, Nektar Therapeutics, Alkermes, Reddy labs, and Millennium pharma. M.G.O. is a consultant for HVH precision analytics, and has research funding from AstraZeneca and Eli Lilly and Company. H.Z. C.L.C. N.S.G. and K.K.W. have ownership interest in a patent application. Funding Information: We thank the NYU Langone Health Preclinical Imaging Laboratory (partially funded by National Institutes of Health (NIH)/National Cancer Institute ( NCI ) 5P30CA016087 and NIH P41 EB017183 ) and the Genome Technology Center (partially supported by P30CA016087 ) for library preparation and sequencing. This work is supported by a Lung Cancer Research Foundation grant (H.Z.), NCI/NIH K99CA201618 (C.L.C.), K08CA222657 (M.G.O.), U01CA213333 (K.K.W. and N.S.G.), and P01 CA154303 (K.K.W.). This work is also supported by the Bridge Project (K.K.W. and N.S.G.), a collaboration between The Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center (DF/HCC). Funding Information: K.K.W. is a founder and equity holder of G1 Therapeutics and has sponsored research agreements with MedImmune , Takeda , TargImmune , Bristol-Myers Squibb (BMS), Mirati , Merus , and Alkermes , and consulting and sponsored research agreements with AstraZeneca , Janssen , Pfizer , Novartis , Merck , Ono , and Array . N.G.S. is a founder, science advisory board member and equity holder in Gatekeeper, Syros, Petra, C4, B2S, and Soltego. The Gray lab receives or has received research funding from Novartis , Takeda , Astellas , Taiho , Janssen , Kinogen , Voronoi , Her2llc , Deerfield , and Sanofi . G.M. has research contract agreements with GlaxoSmithKline, Pfizer, and Puretech Health. V.V. has an advisory/consulting role at Genentech, Merck, BMS, Astrazeneca, Foundation Medicine, Nektar Therapeutics, Alkermes, Reddy labs, and Millennium pharma. M.G.O. is a consultant for HVH precision analytics, and has research funding from AstraZeneca and Eli Lilly and Company . H.Z., C.L.C., N.S.G., and K.K.W. have ownership interest in a patent application. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = jan,

day = "13",

doi = "10.1016/j.ccell.2019.11.003",

language = "English (US)",

volume = "37",

pages = "37--54.e9",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer

AU - Zhang, Hua

AU - Christensen, Camilla L.

AU - Dries, Ruben

AU - Oser, Matthew G.

AU - Deng, Jiehui

AU - Diskin, Brian

AU - Li, Fei

AU - Pan, Yuanwang

AU - Zhang, Xuzhu

AU - Yin, Yandong

AU - Papadopoulos, Eleni

AU - Pyon, Val

AU - Thakurdin, Cassandra

AU - Kwiatkowski, Nicholas

AU - Jani, Kandarp

AU - Rabin, Alexandra R.

AU - Castro, Dayanne M.

AU - Chen, Ting

AU - Silver, Heather

AU - Huang, Qingyuan

AU - Bulatovic, Mirna

AU - Dowling, Catríona M.

AU - Sundberg, Belen

AU - Leggett, Alan

AU - Ranieri, Michela

AU - Han, Han

AU - Li, Shuai

AU - Yang, Annan

AU - Labbe, Kristen E.

AU - Almonte, Christina

AU - Sviderskiy, Vladislav O.

AU - Quinn, Max

AU - Donaghue, Jack

AU - Wang, Eric S.

AU - Zhang, Tinghu

AU - He, Zhixiang

AU - Velcheti, Vamsidhar

AU - Hammerman, Peter S.

AU - Freeman, Gordon J.

AU - Bonneau, Richard

AU - Kaelin, William G.

AU - Sutherland, Kate D.

AU - Kersbergen, Ariena

AU - Aguirre, Andrew J.

AU - Yuan, Guo Cheng

AU - Rothenberg, Eli

AU - Miller, George

AU - Gray, Nathanael S.

AU - Wong, Kwok Kin

N1 - Funding Information: We thank the NYU Langone Health Preclinical Imaging Laboratory (partially funded by National Institutes of Health (NIH)/National Cancer Institute (NCI) 5P30CA016087 and NIH P41 EB017183) and the Genome Technology Center (partially supported by P30CA016087) for library preparation and sequencing. This work is supported by a Lung Cancer Research Foundation grant (H.Z.), NCI/NIH K99CA201618 (C.L.C.), K08CA222657 (M.G.O.), U01CA213333 (K.K.W. and N.S.G.), and P01 CA154303 (K.K.W.). This work is also supported by the Bridge Project (K.K.W. and N.S.G.), a collaboration between The Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center (DF/HCC). H.Z. C.L.C. R.D. N.S.G. and K.K.W. supervised the work, designed all the experiments, and interpreted the data. H.Z. C.L.C. R.D. M.G.O. J.D. B.D. F.L. Y.P. K.J. A.R.R. T.C. M.B. and C.M.D. conducted experiments. E.P. V.P. C.T. and H.S. performed MRI. R.D. D.M.C. G.-C.Y. and R.B. performed bioinformatics analysis. N.K. T.Z. and Z.H. contributed to compound synthesis. X.Z. Y.Y. and E.R. conducted single-cell imaging. H.Z. and K.E.L. conducted MRI analysis. M.G.O. V.O.S. G.M. K.D.S. A.K. A.J.A. and W.G.K. provided critical expertise and/or reagents. All the authors contributed to manuscript preparation. H.Z. C.L.C. R.D. and K.K.W. wrote the manuscript. K.K.W. is a founder and equity holder of G1 Therapeutics and has sponsored research agreements with MedImmune, Takeda, TargImmune, Bristol-Myers Squibb (BMS), Mirati, Merus, and Alkermes, and consulting and sponsored research agreements with AstraZeneca, Janssen, Pfizer, Novartis, Merck, Ono, and Array. N.G.S. is a founder, science advisory board member and equity holder in Gatekeeper, Syros, Petra, C4, B2S, and Soltego. The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voronoi, Her2llc, Deerfield, and Sanofi. G.M. has research contract agreements with GlaxoSmithKline, Pfizer, and Puretech Health. V.V. has an advisory/consulting role at Genentech, Merck, BMS, Astrazeneca, Foundation Medicine, Nektar Therapeutics, Alkermes, Reddy labs, and Millennium pharma. M.G.O. is a consultant for HVH precision analytics, and has research funding from AstraZeneca and Eli Lilly and Company. H.Z. C.L.C. N.S.G. and K.K.W. have ownership interest in a patent application. Funding Information: We thank the NYU Langone Health Preclinical Imaging Laboratory (partially funded by National Institutes of Health (NIH)/National Cancer Institute ( NCI ) 5P30CA016087 and NIH P41 EB017183 ) and the Genome Technology Center (partially supported by P30CA016087 ) for library preparation and sequencing. This work is supported by a Lung Cancer Research Foundation grant (H.Z.), NCI/NIH K99CA201618 (C.L.C.), K08CA222657 (M.G.O.), U01CA213333 (K.K.W. and N.S.G.), and P01 CA154303 (K.K.W.). This work is also supported by the Bridge Project (K.K.W. and N.S.G.), a collaboration between The Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center (DF/HCC). Funding Information: K.K.W. is a founder and equity holder of G1 Therapeutics and has sponsored research agreements with MedImmune , Takeda , TargImmune , Bristol-Myers Squibb (BMS), Mirati , Merus , and Alkermes , and consulting and sponsored research agreements with AstraZeneca , Janssen , Pfizer , Novartis , Merck , Ono , and Array . N.G.S. is a founder, science advisory board member and equity holder in Gatekeeper, Syros, Petra, C4, B2S, and Soltego. The Gray lab receives or has received research funding from Novartis , Takeda , Astellas , Taiho , Janssen , Kinogen , Voronoi , Her2llc , Deerfield , and Sanofi . G.M. has research contract agreements with GlaxoSmithKline, Pfizer, and Puretech Health. V.V. has an advisory/consulting role at Genentech, Merck, BMS, Astrazeneca, Foundation Medicine, Nektar Therapeutics, Alkermes, Reddy labs, and Millennium pharma. M.G.O. is a consultant for HVH precision analytics, and has research funding from AstraZeneca and Eli Lilly and Company . H.Z., C.L.C., N.S.G., and K.K.W. have ownership interest in a patent application. Publisher Copyright: © 2019 Elsevier Inc.

PY - 2020/1/13

Y1 - 2020/1/13

N2 - Cyclin-dependent kinase 7 (CDK7) is a central regulator of the cell cycle and gene transcription. However, little is known about its impact on genomic instability and cancer immunity. Using a selective CDK7 inhibitor, YKL-5-124, we demonstrated that CDK7 inhibition predominately disrupts cell-cycle progression and induces DNA replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously triggering immune-response signaling. These tumor-intrinsic events provoke a robust immune surveillance program elicited by T cells, which is further enhanced by the addition of immune-checkpoint blockade. Combining YKL-5-124 with anti-PD-1 offers significant survival benefit in multiple highly aggressive murine models of SCLC, providing a rationale for new combination regimens consisting of CDK7 inhibitors and immunotherapies.

AB - Cyclin-dependent kinase 7 (CDK7) is a central regulator of the cell cycle and gene transcription. However, little is known about its impact on genomic instability and cancer immunity. Using a selective CDK7 inhibitor, YKL-5-124, we demonstrated that CDK7 inhibition predominately disrupts cell-cycle progression and induces DNA replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously triggering immune-response signaling. These tumor-intrinsic events provoke a robust immune surveillance program elicited by T cells, which is further enhanced by the addition of immune-checkpoint blockade. Combining YKL-5-124 with anti-PD-1 offers significant survival benefit in multiple highly aggressive murine models of SCLC, providing a rationale for new combination regimens consisting of CDK7 inhibitors and immunotherapies.

KW - CDK7

KW - YKL-5-124

KW - anti-tumor immunity

KW - cell cycle

KW - genome instability

KW - immune checkpoint blockade

KW - immunotherapy

KW - replication stress

KW - single-cell analysis

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85077376602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077376602&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2019.11.003

DO - 10.1016/j.ccell.2019.11.003

M3 - Article

C2 - 31883968

AN - SCOPUS:85077376602

VL - 37

SP - 37-54.e9

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 1

ER -

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this